Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POPular GUILTY pilot: genotype-guided clopidogrel monotherapy
NL-OMON53943Phase 4Recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clopidogrel in acute coronary syndrome (ACS), Non-ST-segment elevation myocardial infarction (NSTEMI), unstable angina and 1 more, sponsored by St. Antonius Ziekenhuis. Primary endpoints: Primary ischemic endpoint at 6 months and Primary bleeding endpoint at 6 months. Started Jul 2023; status: recruiting.
02
Drugs
clopidogrel
03
Conditions
acute coronary syndrome (ACS)Non-ST-segment elevation myocardial infarction (NSTEMI)unstable anginacoronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON53943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53943.